HPV Vaccine Protection Lasts Over 12 Years

Summary of the HPV Vaccine Study in Scotland

This article details a study investigating the long-term effectiveness of the HPV vaccine in preventing high-grade cervical lesions in Scotland.Here’s a breakdown of the key findings:

* Long-lasting Protection: The HPV vaccine remains highly effective (72.6% for CIN2+ and 81.7% for CIN3+) more than 12 years after vaccination,with only a slight decline in⁢ protection with age.
* age matters: ⁣ Vaccination is most‍ effective when administered around age 12-13, before sexual activity‌ begins. Vaccination after age 18 showed no measurable benefit,⁢ as ‌the vaccine prevents new ⁢ infections, not persistent ones.
* Herd Protection: High vaccination rates have led to meaningful “herd protection,” meaning unvaccinated women also experience lower⁢ rates of disease due to reduced HPV transmission.
* Reduced Health Inequalities: The vaccine has been ⁢especially⁢ effective in protecting women in more​ deprived areas, helping to reduce existing health⁢ disparities.
* Study Methodology: Researchers analyzed data ⁢from over 271,000 women born between 1988 and 1996, comparing rates of high-grade cervical changes (CIN2+ and CIN3+) between vaccinated (complete, incomplete) and unvaccinated groups.
* CIN2+ & CIN3+ Explained: These ⁢are pre-cancerous ⁤cervical lesions ‍- CIN2+ includes CIN2, CIN3, and cervical cancer,⁢ while CIN3+ includes CIN3 and cervical ⁣cancer.

In essence, the study provides strong evidence supporting the continued success of Scotland’s HPV vaccination program and reinforces the importance of early vaccination for lasting protection against cervical cancer.